Product
Help
Pricing
About
Jobs
Log in
Get started
Concept
Add to collection
BRCA mutation
OpenAlex ID:
C2780194787
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
2003
·
A. Antoniou
, P.D.P. Pharoah
, et al.
·
The American Journal of Human Genetics
·
4,465
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009
·
Peter C. Fong
, David S. Boss
, et al.
·
New England Journal of Medicine
·
4,078
PDF
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017
·
Mark Robson
, Seock-Ah Im
, et al.
·
New England Journal of Medicine
·
3,774
PDF
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010
·
M William Audeh
, James Carmichael
, et al.
·
The Lancet
·
2,420
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
2019
·
Isabelle Ray-Coquard
, Patricia Pautier
, et al.
·
New England Journal of Medicine
·
2,282
PDF
Meta-Analysis of BRCA1 and BRCA2 Penetrance
2007
·
Sining Chen
, Giovanni Parmigiani
·
Journal of Clinical Oncology
·
2,174
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
2017
·
Eric Pujade-Lauraine
, Jonathan A Ledermann
, et al.
·
The Lancet Oncology
·
2,054
PDF
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010
·
Andrew Tutt
, Mark Robson
, et al.
·
The Lancet
·
1,878
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014
·
Bella Kaufman
, Ronnie Shapira-Frommer
, et al.
·
Journal of Clinical Oncology
·
1,849
PDF
Cancer Risks in BRCA2 Mutation Carriers
1999
·
The Breast Cancer Linkage Consortium
·
JNCI Journal of the National Cancer Institute
·
1,743
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
·
Jonathan Ledermann
, Philipp Harter
, et al.
·
The Lancet Oncology
·
1,594
Risk-Reducing Salpingo-oophorectomy in Women with aBRCA1orBRCA2Mutation
2002
·
Noah D. Kauff
, Jaya M. Satagopan
, et al.
·
New England Journal of Medicine
·
1,430
PDF
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
2012
·
Kathryn Alsop
, Sian Fereday
, et al.
·
Journal of Clinical Oncology
·
1,340
PDF
Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group
2004
·
Timothy R. Rebbeck
, Tara Friebel
, et al.
·
Journal of Clinical Oncology
·
1,321
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
·
Karen A Gelmon
, Marc Tischkowitz
, et al.
·
The Lancet Oncology
·
1,202
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
2013
·
Nasim Mavaddat
, Susan Peock
, et al.
·
JNCI Journal of the National Cancer Institute
·
1,118
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
2010
·
Peter C. Fong
, Timothy A. Yap
, et al.
·
Journal of Clinical Oncology
·
1,109
PDF
Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers
2009
·
T. R. Rebbeck
, N. D. Kauff
, et al.
·
JNCI Journal of the National Cancer Institute
·
1,048
PDF
BRCA1 Testing in Families With Hereditary Breast-Ovarian Cancer: A Prospective Study of Patient Decision Making and Outcomes
1996
·
Caryn Lerman
·
JAMA
·
879
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
2019
·
M.E. Robson
, N. Tung
, et al.
·
Annals of Oncology
·
870
Breast Cancer Epidemiology, Prevention, and Screening
2017
·
Stella Winters
, Charmaine Martin
, et al.
·
Progress in molecular biology and translational science
·
826
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
2001
·
L. C. Hartmann
, T. A. Sellers
, et al.
·
JNCI Journal of the National Cancer Institute
·
823
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
2005
·
Tuya Pal
, Jenny Permuth‐Wey
, et al.
·
Cancer
·
805
Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 Mutation
2006
·
Amy Finch
, Mario Beiner
, et al.
·
JAMA
·
700
PDF
Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer
2008
·
Deann P. Atchley
, Constance T. Albarracin
, et al.
·
Journal of Clinical Oncology
·
679
Show more works
View as search
Works count:
6,258
Citation count:
175,100
Year
Topic
Type